HK StockDetailed Quotes

Provided by TTMF Limited

BIOKINUnlisted

Volume:- -

Turnover:- -

Market Cap:- -

PE:- -

High:- -

Open:- -

Low:- -

Close:- -

52wk High:- -

52wk Low:- -

Shares:421.51M

HK Float Shares:421.51M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:-14.94%

ROA:-5.41%

PB:0.00

PE(LYR):- -

PS:0.00

1

Offering

Nov 07

2

Closed

Nov 12 09:30

3

IPO Result

Nov 13

4

Grey Mkt.

Dec 31 16:15 - 18:30

5

Listing

Nov 17

Overview Company News Filings

Price Range

347.50 ~ 389.00 HKD

Listing Price

- -

Issue Volume

8.63M

Estimated Mkt Cap

146.47B ~ 163.97B HKD

Min Amount

100

Underwrither

Goldman Sachs (Asia) L.L.C.

View Prospectus

News

BIOKIN (688506.SH): Iza-bren (EGFR×HER3 Bispecific ADC) for Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Included in Priority Review Program

Over 160 Billion Yuan in Lock-Up Shares to Flood Market Next Week, Three Stocks Face Over 10 Billion Yuan in Lifting Restrictions

Sichuan Biokin Pharmaceutical (688506.SH) Subsidiary Receives $250 Million Milestone Payment from Bristol-Myers Squibb for Iza-Bren Project

Sichuan Biokin Pharmaceutical Gets Acceptance for Cancer Drug Application

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02615"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02615","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02615\",,,,,undefined,":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"BIOKIN","latestPrice":0,"timestamp":1770364800000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":421508117,"shares":421508117,"eps":0,"marketStatus":"To be listed","change":0,"latestTime":"02-06 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.204,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":4102450200000},"marketStatusCode":8,"adr":0,"listingDate":4102416000000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1770341400000,1770350400000],[1770354000000,1770364800000]],"volumeRatio":0,"ipoDetail":{"name":"百利天恒","exchange":"SEHK","listingDate":"2100-01-01","sharesOutstanding":421508117,"sharesFloat":421508117,"offerAmount":8634300,"priceRange":"347.500 - 389.000","market":"HK","openProspectusDate":"2025-11-07","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","purchaseBeginDate":"2025-11-07","purchaseEndDate":"2025-11-12","winningDate":"2025-11-14","currency":"HKD","minPurchaseQuantity":100,"peRate":39.25,"use":"1、约60.0%或1,810.5百万港元将用于拨付于中国内地以外地区的生物候选药物的研发活动；\n2、约30.0%或905.2百万港元将用于建立全球供应链，主要为在中国内地以外地区的生物候选药物的新生产设施的建设或潜在收购机会提供资金；\n3、约10.0%或301.7百万港元将用于拨付在中国内地以外业务的营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","subscribed":19.93,"marketCap":146474000000,"minimumCapital":39292.31,"overAllotment":false,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700"},"greyMarketDetail":{"greyDate":"2099-12-31","greyDateTimestamp":4102329600000,"greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"showGreyQuote":false,"openProspectusDate":"2025-11-07","listingDate":"2100-01-01"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"Sichuan Biokin Pharmaceutical Co.,Ltd.","latestPrice":281,"timestamp":1770361200000,"preClose":282.83,"halted":0,"volume":1278300,"delay":0,"premium":"-100.00"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02615\",,,,,undefined,":{"symbol":"02615","floatShares":421508117,"roa":"-5.41%","roe":"-14.94%","lyrEps":0,"shares":421508117,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"0.00","psRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.204,"open":0},"@#url:\"https://hktrade.skytigris.com/ipos/general/02615\",,undefined,":{"id":9063,"type":"COMMON","ipoName":"02615-IPO","symbol":"02615","companyName":"BIOKIN","market":"HK","currency":"HKD","status":"CANCELLED","underwriter":"Goldman Sachs (Asia) L.L.C.","lotSize":100,"minQty":100,"expectedOfferingSize":8634300,"openingDate":1762479000000,"closingDate":1762911000000,"commonClosingDate":1762911000000,"allotmentDate":1762963200000,"listDate":1763308800000,"marginable":true,"latestPrice":389,"minPrice":347.5,"maxPrice":389,"prospectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700013.pdf","allowedQuantities":[100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700],"recommend":false,"isHint":false,"interestStartDate":1762876800000,"interestEndDate":1762876800000,"delayAllocate":false,"isSupportGreyMarket":true,"greyMarketTradeDate":1763108100000,"transactionRate":0.010085,"gstFeeRate":0,"rank":0,"subscribed":false,"signed":false,"financingInfos":[],"financingNotifyEnabled":false,"financingNotifySubscribed":false,"subscriptionMethods":[],"latestClosingDate":1770468961067,"subscribedFinanceRatio":19.93,"subscribedRatio":19.93,"forecastRatio":24.31,"raiseMoney":335900000,"totalMargin":6694640000,"quoteInfoUpdatedAt":1770448543176,"prospectusUpdatedAt":1762928848000,"forecastMarketValue":155220364085.25,"minForecastMarketValue":146474070657.5,"maxForecastMarketValue":163966657513,"sharesOutstanding":421508117,"business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"tradable":false,"showClawback":false},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02615\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1162586133","title":"BIOKIN (688506.SH): Iza-bren (EGFR×HER3 Bispecific ADC) for Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma Included in Priority Review Program","url":"https://stock-news.laohu8.com/highlight/detail?id=1162586133","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162586133?lang=en_us&edition=fundamental","pubTime":"2026-01-06 16:58","pubTimestamp":1767689914,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co.,Ltd. (688506.SH) announced that its self-developed, first-in-class, new-concept bispecific ADC (Antibody-Drug Conjugate) iza-bren for injection has been included in...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["91194","688506","BK0239","BK4231","02615","BK4080","ADC"],"gpt_icon":0},{"id":"1180985873","title":"Over 160 Billion Yuan in Lock-Up Shares to Flood Market Next Week, Three Stocks Face Over 10 Billion Yuan in Lifting Restrictions","url":"https://stock-news.laohu8.com/highlight/detail?id=1180985873","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180985873?lang=en_us&edition=fundamental","pubTime":"2026-01-04 21:41","pubTimestamp":1767534096,"startTime":"0","endTime":"0","summary":"According to Wind data, during the week of January 5th to 9th, a total of 37 A-share companies will see their restricted shares become eligible for trading, with the combined lifted market value...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02615"],"gpt_icon":0},{"id":"1169803746","title":"Sichuan Biokin Pharmaceutical (688506.SH) Subsidiary Receives $250 Million Milestone Payment from Bristol-Myers Squibb for Iza-Bren Project","url":"https://stock-news.laohu8.com/highlight/detail?id=1169803746","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169803746?lang=en_us&edition=fundamental","pubTime":"2025-11-30 17:00","pubTimestamp":1764493215,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical Co., Ltd. (688506.SH) announced that its wholly-owned subsidiary, SystImmune, recently received a $250 million milestone payment from Bristol-Myers Squibb (BMY)....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505439.SGD","IE0002141913.USD","IE0009355771.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4581","BK4007","LU1032466523.USD","LU1093756325.SGD","LU1868837136.USD","LU0985481810.HKD","LU0096364046.USD","LU1585245621.USD","BK4588","02615","LU1868837300.USD","LU1868836757.USD","IE00BFTCPJ56.SGD","LU1571399168.USD","IE00BJT1NW94.SGD","LU0225771236.USD","LU0267386448.USD","LU1093756168.USD","LU2242652126.USD","LU0114720955.EUR","IE00BSNM7G36.USD","LU0882574055.USD","LU1718418525.SGD","BK4559","LU1868836591.USD","BK0239","IE00BFXG1179.USD","LU1670710661.SGD","LU2125154778.USD","LU2133065610.SGD","LU0868494617.USD","LU1261432733.SGD","LU1670710588.SGD","LU1670711123.USD","LU1989771016.USD","LU1868836914.USD","LU0061475181.USD","LU0225284248.USD","BK4585","LU1291159041.SGD","LU1323610961.USD","LU2125154935.USD","BMY","LU2242646821.SGD","LU2360032135.SGD","688506","BK4532","LU0237698245.USD","LU0306807586.USD","LU0306806265.USD","BK4534","LU0321505868.SGD","LU1430594728.SGD","LU1074936037.SGD","LU0456855351.SGD","91194","LU1670711040.USD"],"gpt_icon":0},{"id":"2585437299","title":"Sichuan Biokin Pharmaceutical Gets Acceptance for Cancer Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2585437299","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585437299?lang=en_us&edition=fundamental","pubTime":"2025-11-24 11:52","pubTimestamp":1763956368,"startTime":"0","endTime":"0","summary":"Sichuan Biokin Pharmaceutical  said its new drug application for innovative cancer treatment iza-bren has been accepted by China's medical products administrator.The drug is intended for locally advanced or metastatic nasopharyngeal carcinoma that failed prior treatments, according to a Monday filing with the Shanghai bourse.Shares of the pharmaceutical company were up 1% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02615","688506","BK0239"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}